Received Apr 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
headache, fever, body ache, joint pain; fever; body ache; joint pain; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of headache in a patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on an unknown date). On 09-APR-2026, the patient received the 2nd dose of Shingrix. In APR-2026, an unknown time after receiving Shingrix, the patient experienced headache (Verbatim: headache, fever, body ache, joint pain), fever (Verbatim: fever), general body pain (Verbatim: body ache) and joint pain (Verbatim: joint pain). The outcome of the headache was not applicable and the outcome of the fever, general body pain and joint pain were not reported. It was unknown if the reporter considered the headache, fever, general body pain and joint pain to be related to Shingrix. It was unknown if the company considered the headache, fever, general body pain and joint pain to be related to Shingrix. Additional Information: GSK receipt date: 11-APR-2026 The patient received second dose of Shingrix two days prior reporting, patient was experiencing side effects such as headache, fever, body ache, joint pain, pain all over, asked what over the counter medication can I take. The batch number was not provided, and we are unable to contact the reporter.